-
公开(公告)号：US20180362643A1
公开(公告)日：2018-12-20
申请号：US16063152
申请日：2016-12-15
Applicant: AMGEN INC.
Inventor： Agnes E. HAMBURGER , Cen XU , Hong SUN , Yuan D. SHIH , Dohan WEERARATNE
CPC classification number: C07K16/26 , A61K9/0019 , A61K2039/505 , A61P25/06 , C07K16/4283 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/76
Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
-
12.发明申请公开(公告)号：US20170306033A1
公开(公告)日：2017-10-26
申请号：US15511176
申请日：2015-09-15
Applicant: AMGEN INC.
Inventor： Gunasekaran KANNAN , Ling LIU , Edward J. BELOUSKI , Cen XU
IPC: C07K16/28
CPC classification number: C07K16/2869 , C07K16/18 , C07K16/28 , C07K2317/31 , C07K2317/35 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/70 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.
-
公开(公告)号：US20150010560A1
公开(公告)日：2015-01-08
申请号：US14304559
申请日：2014-06-13
Applicant: Amgen Inc.
Inventor： Cen XU , Agnes Eva HAMBURGER
IPC: C07K16/28
CPC classification number: C07K16/28 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
Abstract translation: 提供了结合人PAC1的抗体及其抗原结合片段。 还提供了编码抗体及其抗原结合片段，载体和编码其的细胞的核酸。 抗体及其抗原结合片段可以抑制PAC1与PACAP的结合，并且可用于许多PAC1相关疾病，包括治疗和/或预防头痛障碍，包括偏头痛。
-
公开(公告)号：US20250129172A1
公开(公告)日：2025-04-24
申请号：US18904787
申请日：2024-10-02
Applicant: AMGEN INC.
Inventor： Thomas C. BOONE , David W. BRANKOW , Colin V. GEGG, JR. , Shaw-Fen Sylvia HU , Chadwick T. KING , Hsieng Sen LU , Licheng SHI , Cen XU
Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
-
公开(公告)号：US20240150448A1
公开(公告)日：2024-05-09
申请号：US18545688
申请日：2023-12-19
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
CPC classification number: C07K16/18 , A61K38/2278 , A61P25/06 , C07K16/2869 , A61K2039/545 , C07K2317/34 , C07K2317/565 , C07K2317/92
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
Patent Agency Ranking
公开(公告)号：US20220363770A1
公开(公告)日：2022-11-17
申请号：US17621189
申请日：2020-06-26
Applicant: AMGEN INC.
Inventor： Irwin CHEN , Su CHONG , Fernando GARCES , Mark Leo MICHAELS , Christopher MOHR , Kenneth William WALKER , Zhulun WANG , Neeraj Jagdish AGRAWAL , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Derek E. PIPER , Cen XU
Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.
-
公开(公告)号：US20220195022A1
公开(公告)日：2022-06-23
申请号：US17558032
申请日：2021-12-21
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20210179723A1
公开(公告)日：2021-06-17
申请号：US17111453
申请日：2020-12-03
Applicant: AMGEN INC.
Inventor： Thomas C. BOONE , David W. BRANKOW , Colin V. GEGG, Jr. , Shaw-Fen Sylvia HU , Chadwick T. KING , Hsieng Sen LU , Licheng SHI , Cen XU
IPC: C07K16/28 , A61K39/395
Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
-
公开(公告)号：US20180362645A1
公开(公告)日：2018-12-20
申请号：US16017891
申请日：2018-06-25
Applicant: AMGEN INC.
Inventor： Cen XU , Agnes Eva HAMBURGER
IPC: C07K16/28
CPC classification number: C07K16/28 , A61P25/06 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
-
公开(公告)号：US20180142029A1
公开(公告)日：2018-05-24
申请号：US15824827
申请日：2017-11-28
Applicant: AMGEN INC.
Inventor： Thomas C. BOONE , David W. BRANKOW , Colin V. GEGG, JR. , Shaw-Fen Sylvia HU , Chadwick T. KING , Hsieng Sen LU , Licheng SHI , Cen XU
IPC: C07K16/28 , A61K39/395 , A61K39/00
CPC classification number: C07K16/2869 , A61K39/395 , A61K39/39533 , A61K2039/505 , C07K2317/21 , C07K2317/32 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/30
Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.028 seconds)
